TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomised Controlled Study on the Effectiveness of Cupping Massage for Home Use in Chronic Neck Pain [Randomisierte Kontrollierte Studie Zur Wirksamkeit Der Schröpfkopfmassage Als Heimanwendung Bei Chronischen Nackenschmerzen]
Brief Summary: The purpose of this randomized controlled study is to determine the effectiveness of cupping massage as home use for patients with chronic nonspecific neck pain compared to relaxation exercise.


Options:
A: Arm Label: cupping massage; Type: EXPERIMENTAL; Interventions: Procedure: cupping massage | Arm Label: control group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Progressive muscle relaxation | Intervention Type: PROCEDURE; Name: cupping massage; Assigned to Arm(s): cupping massage | Intervention Type: PROCEDURE; Name: Progressive muscle relaxation; Assigned to Arm(s): control group
B: Arm Label: Waiting list control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Treatment group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Dry Cupping or fire cupping | Intervention Type: PROCEDURE; Name: Dry Cupping or fire cupping; Assigned to Arm(s): Treatment group
C: Arm Label: Exercise and connective tissue massage; Type: EXPERIMENTAL; Interventions: Behavioral: "Exercise" and "connective tissue massage" | Arm Label: Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: "Exercise" | Intervention Type: BEHAVIORAL; Name: "Exercise" and "connective tissue massage"; Assigned to Arm(s): Exercise and connective tissue massage | Intervention Type: BEHAVIORAL; Name: "Exercise"; Assigned to Arm(s): Exercise
D: Arm Label: Craniosacral Therapy (CST); Type: EXPERIMENTAL; Interventions: Procedure: Craniosacral Therapy | Arm Label: Sham Craniosacral Therapy (SHAM); Type: SHAM_COMPARATOR; Interventions: Procedure: Sham Craniosacral Therapy | Intervention Type: PROCEDURE; Name: Craniosacral Therapy; Assigned to Arm(s): Craniosacral Therapy (CST) | Intervention Type: PROCEDURE; Name: Sham Craniosacral Therapy; Assigned to Arm(s): Sham Craniosacral Therapy (SHAM)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Establishing Cardiovascular Biomarkers to Define Preferred Lantus® Use.
Brief Summary: The aim of this study is to observe changes in cardiovascular biomarkers during treatment with Lantus in patients with Type 2 Diabetes mellitus.


Options:
A: Arm Label: NPH insulin + insulin glulisine; Type: ACTIVE_COMPARATOR; Interventions: Drug: nph insulin, Drug: Insulin glulisine | Arm Label: NPH insulin + human insulin; Type: ACTIVE_COMPARATOR; Interventions: Drug: human insulin | Arm Label: Insulin glargine + insulin glulisine; Type: EXPERIMENTAL; Interventions: Drug: Insulin Glargine, Drug: Insulin glulisine | Arm Label: Insulin Glargine + Human insulin; Type: EXPERIMENTAL; Interventions: Drug: human insulin, Drug: Insulin Glargine | Intervention Type: DRUG; Name: nph insulin; Assigned to Arm(s): NPH insulin + insulin glulisine | Intervention Type: DRUG; Name: human insulin; Assigned to Arm(s): Insulin Glargine + Human insulin, NPH insulin + human insulin | Intervention Type: DRUG; Name: Insulin Glargine; Assigned to Arm(s): Insulin Glargine + Human insulin, Insulin glargine + insulin glulisine | Intervention Type: DRUG; Name: Insulin glulisine; Assigned to Arm(s): Insulin glargine + insulin glulisine, NPH insulin + insulin glulisine
B: Arm Label: 1. Insulatard; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulatard | Arm Label: 2. Detemir; Type: ACTIVE_COMPARATOR; Interventions: Drug: Detemir | Intervention Type: DRUG; Name: Insulatard; Assigned to Arm(s): 1. Insulatard | Intervention Type: DRUG; Name: Detemir; Assigned to Arm(s): 2. Detemir
C: Intervention Type: DRUG; Name: insulin detemir; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: insulin NPH; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: insulin aspart; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Insulin Glargine (HOE901)/NPH Insulin | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Insulin Glargine (HOE901)/NPH Insulin | Intervention Type: DRUG; Name: Insulin Glargine (HOE901)/NPH Insulin; Assigned to Arm(s): 1, 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: 5-Fluorouracil Versus Capecitabine as Perioperative Treatment for Locally Advanced Rectal Cancer. a Randomized Phase III Trial
Brief Summary: This study compares capecitabine with standard 5-FU in the perioperative treatment of locally advanced rectal cancer.


Options:
A: Arm Label: S-1 and Oxaliplatin; Type: EXPERIMENTAL; Interventions: Drug: S-1 & Oxaliplatin | Arm Label: Capecitabine and Oxaliplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Capecitabine & Oxaliplatin | Intervention Type: DRUG; Name: S-1 & Oxaliplatin; Assigned to Arm(s): S-1 and Oxaliplatin | Intervention Type: DRUG; Name: Capecitabine & Oxaliplatin; Assigned to Arm(s): Capecitabine and Oxaliplatin
B: Arm Label: 5-Fluorouracil (5-FU); Type: ACTIVE_COMPARATOR; Interventions: Drug: 5-FU | Arm Label: Capecitabine; Type: EXPERIMENTAL; Interventions: Drug: Capecitabine | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): Capecitabine | Intervention Type: DRUG; Name: 5-FU; Assigned to Arm(s): 5-Fluorouracil (5-FU)
C: Intervention Type: DRUG; Name: fluorouracil; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: leucovorin calcium; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A
D: Arm Label: FOLFIRI +/- Bevacizumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Bevacizumab, Drug: CPT-11 (Irinotecan), Drug: 5-FU Bolus, Drug: 5-FU Infusion, Drug: l-LV (dl-LV) | Arm Label: XELIRI +/- Bevacizumab; Type: EXPERIMENTAL; Interventions: Biological: bevacizumab, Drug: CPT-11 (Irinotecan), Drug: Capecitabine | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): FOLFIRI +/- Bevacizumab | Intervention Type: DRUG; Name: CPT-11 (Irinotecan); Assigned to Arm(s): FOLFIRI +/- Bevacizumab | Intervention Type: DRUG; Name: 5-FU Bolus; Assigned to Arm(s): FOLFIRI +/- Bevacizumab | Intervention Type: DRUG; Name: 5-FU Infusion; Assigned to Arm(s): FOLFIRI +/- Bevacizumab | Intervention Type: DRUG; Name: l-LV (dl-LV); Assigned to Arm(s): FOLFIRI +/- Bevacizumab | Intervention Type: BIOLOGICAL; Name: bevacizumab; Assigned to Arm(s): XELIRI +/- Bevacizumab | Intervention Type: DRUG; Name: CPT-11 (Irinotecan); Assigned to Arm(s): XELIRI +/- Bevacizumab | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): XELIRI +/- Bevacizumab

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Exercise Training in Primary Sjogren´s Syndrome, Myositis and Takayasu's Arteritis
Brief Summary: Exercise may improve physical capacity and health parameters in Primary Syndrome´s Sjogren, Myositis and Takayasu's Arteritis.

Therefore, this study aims to investigate the role of an exercise training program in patients with Primary Syndrome´s Sjogren, Myositis and Takayasu's Arteritis.


Options:
A: Arm Label: Energetic; Type: EXPERIMENTAL; Interventions: Behavioral: Energetic | Arm Label: Control group; Type: OTHER; Interventions: Other: Control group | Intervention Type: BEHAVIORAL; Name: Energetic; Assigned to Arm(s): Energetic | Intervention Type: OTHER; Name: Control group; Assigned to Arm(s): Control group
B: Arm Label: Exercise; Type: EXPERIMENTAL; Interventions: Other: Exercise on a cycle-ergometer | Arm Label: Controls; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Exercise on a cycle-ergometer; Assigned to Arm(s): Exercise
C: Arm Label: Sjogren and Myositis Control (no control for takayasu's); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Sjogren, Myositis and Takayasu's Trained; Type: EXPERIMENTAL; Interventions: Other: Exercise training | Intervention Type: OTHER; Name: Exercise training; Assigned to Arm(s): Sjogren, Myositis and Takayasu's Trained
D: Arm Label: Behavioural change intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioural change intervention | Arm Label: Standard Patient Management; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Behavioural change intervention; Assigned to Arm(s): Behavioural change intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Double Blind Comparison of Atosiban in Patients Undergoing in Vitro Fertilization Treatment
Brief Summary: The hypothesis of this randomized double blind study is that the live birth rates are significantly higher after the use of atosiban prior to the embryo transfer in patients undergoing in vitro fertilization (IVF) treatment. This study aims to compare the live birth rates of IVF treatment between patients receiving atosiban and placebo prior to the transfer.


Options:
A: Arm Label: Nolasiban 900 mg; Type: EXPERIMENTAL; Interventions: Drug: Nolasiban 900mg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Nolasiban 900mg; Assigned to Arm(s): Nolasiban 900 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Atosiban; Type: ACTIVE_COMPARATOR; Interventions: Drug: Atosiban | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal saline | Intervention Type: DRUG; Name: Atosiban; Assigned to Arm(s): Atosiban | Intervention Type: DRUG; Name: Normal saline; Assigned to Arm(s): Placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: PIPELLE ENDOMETRIAL SAMPLING | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: PIPELLE ENDOMETRIAL SAMPLING; Assigned to Arm(s): 1
D: Arm Label: OBE001 dose 1; Type: EXPERIMENTAL; Interventions: Drug: OBE001 dose 1 | Arm Label: OBE001 dose 2; Type: EXPERIMENTAL; Interventions: Drug: OBE001 dose 2 | Arm Label: OBE001 dose 3; Type: EXPERIMENTAL; Interventions: Drug: OBE001 dose 3 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: OBE001 dose 1; Assigned to Arm(s): OBE001 dose 1 | Intervention Type: DRUG; Name: OBE001 dose 2; Assigned to Arm(s): OBE001 dose 2 | Intervention Type: DRUG; Name: OBE001 dose 3; Assigned to Arm(s): OBE001 dose 3 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The recent controversy regarding the use of pill for cycle planning in GnRH antagonists IVF cycle has driven the search for new ways to plan IVF cycles in order to avoid weekends or to equally distribute the workload. Recently, mid-late luteal phase oral estrogens seem to be as good as the pill. The investigators will compare OCP vs oral estrogens to plan the initiation of IVF cycles.


Options:
A: Arm Label: fresh embryo transfer group; Type: EXPERIMENTAL; Interventions: Other: fresh embryo transfer | Arm Label: frozen-thawed embryo transfer group; Type: EXPERIMENTAL; Interventions: Other: frozen-thawed embryo transfer | Intervention Type: OTHER; Name: fresh embryo transfer; Assigned to Arm(s): fresh embryo transfer group | Intervention Type: OTHER; Name: frozen-thawed embryo transfer; Assigned to Arm(s): frozen-thawed embryo transfer group
B: Arm Label: OCP; Type: ACTIVE_COMPARATOR; Interventions: Drug: Levonorgestrel and ethinylestradiol | Arm Label: Oral estradiol valerate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Estradiol valerate | Intervention Type: DRUG; Name: Levonorgestrel and ethinylestradiol; Assigned to Arm(s): OCP | Intervention Type: DRUG; Name: Estradiol valerate; Assigned to Arm(s): Oral estradiol valerate
C: Arm Label: natural cycle; Type: OTHER; Interventions: Other: embryo transfer | Arm Label: hormonal cycle; Type: ACTIVE_COMPARATOR; Interventions: Other: embryo transfer | Intervention Type: OTHER; Name: embryo transfer; Assigned to Arm(s): hormonal cycle, natural cycle
D: Arm Label: 150 µg Corifollitropin Alfa; Type: EXPERIMENTAL; Interventions: Drug: Corifollitropin alfa, Drug: Placebo RecFSH / follitropin beta, Biological: RecFSH / Follitropin beta (Days 8 to hCG), Drug: Ganirelix, Biological: hCG, Biological: Progesterone | Arm Label: 200 IU recFSH; Type: ACTIVE_COMPARATOR; Interventions: Biological: RecFSH / Follitropin beta (Days 1 to 7), Drug: Placebo Corifollitropin alfa, Biological: RecFSH / Follitropin beta (Days 8 to hCG), Drug: Ganirelix, Biological: hCG, Biological: Progesterone | Intervention Type: DRUG; Name: Corifollitropin alfa; Assigned to Arm(s): 150 µg Corifollitropin Alfa | Intervention Type: BIOLOGICAL; Name: RecFSH / Follitropin beta (Days 1 to 7); Assigned to Arm(s): 200 IU recFSH | Intervention Type: DRUG; Name: Placebo Corifollitropin alfa; Assigned to Arm(s): 200 IU recFSH | Intervention Type: DRUG; Name: Placebo RecFSH / follitropin beta; Assigned to Arm(s): 150 µg Corifollitropin Alfa | Intervention Type: BIOLOGICAL; Name: RecFSH / Follitropin beta (Days 8 to hCG); Assigned to Arm(s): 150 µg Corifollitropin Alfa, 200 IU recFSH | Intervention Type: DRUG; Name: Ganirelix; Assigned to Arm(s): 150 µg Corifollitropin Alfa, 200 IU recFSH | Intervention Type: BIOLOGICAL; Name: hCG; Assigned to Arm(s): 150 µg Corifollitropin Alfa, 200 IU recFSH | Intervention Type: BIOLOGICAL; Name: Progesterone; Assigned to Arm(s): 150 µg Corifollitropin Alfa, 200 IU recFSH

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase II Intravenous Autologous Bone Marrow-derived Stem Cells Therapy for Patients With Acute Ischemic Stroke
Brief Summary: A multi-centric initiative to study safety,feasibility and efficacy of using intravenous autologous bone marrow mononuclear cells(BMMC) in patients with acute ischemic stroke.This phase of study is visualised as phase 2 study and will aim to determine dose response gradient of stem cell therapy and to explore if there is favorable risk to benefit ratio for autologous stem cell therapy in patient with acute ischamic stroke.


Options:
A: Arm Label: Stem Cells; Type: EXPERIMENTAL; Interventions: Biological: Autologous bone marrow mononuclear cell transplantation | Intervention Type: BIOLOGICAL; Name: Autologous bone marrow mononuclear cell transplantation; Assigned to Arm(s): Stem Cells
B: Arm Label: CTX0E03 DP; Type: EXPERIMENTAL; Interventions: Biological: CTX0E03 neural stem cells | Intervention Type: BIOLOGICAL; Name: CTX0E03 neural stem cells; Assigned to Arm(s): CTX0E03 DP
C: Arm Label: Cohort 1; Type: EXPERIMENTAL; Interventions: Biological: MultiStem, Biological: Placebo | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Biological: MultiStem, Biological: Placebo | Arm Label: Cohort 3; Type: EXPERIMENTAL; Interventions: Biological: MultiStem, Biological: Placebo | Intervention Type: BIOLOGICAL; Name: MultiStem; Assigned to Arm(s): Cohort 1, Cohort 2, Cohort 3 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Cohort 1, Cohort 2, Cohort 3
D: Arm Label: Autologous bone marrow stem cell; Type: EXPERIMENTAL; Interventions: Biological: Autologous bone marrow stem cell | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Autologous bone marrow stem cell; Assigned to Arm(s): Autologous bone marrow stem cell

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Trial Comparing the Standard and Fanning Techniques for Fine Needle Aspiration of Pancreatic Mass Lesions at Endoscopic Ultrasound
Brief Summary: Endoscopic Ultrasound (EUS)-guided biopsy is the most ideal technique for evaluating a growth in the pancreas. EUS-guided biopsies yield a definitive diagnosis in greater than 80% of cases. In 15-20% of the cases, a definitive diagnosis cannot be made despite multiple attempts. One of the reasons why a diagnosis cannot be made is due to the focal location of the cancer; i.e., the cancer can be situated in a corner of a big mass and the needle fails to sample the cancer cells. The fanning technique is a method where the needle moves in multiple directions within a mass and therefore there is a better chance of the cancer cells being sampled compared to the standard technique where the needle moves in only one direction. The diagnostic performance of both these techniques has not been compared in a randomized fashion.


Options:
A: Arm Label: Standard; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard | Arm Label: Fanning; Type: OTHER; Interventions: Procedure: Fanning | Intervention Type: PROCEDURE; Name: Standard; Assigned to Arm(s): Standard | Intervention Type: PROCEDURE; Name: Fanning; Assigned to Arm(s): Fanning
B: Arm Label: Lymph nodes, pancreatic masses & cysts; Type: OTHER; Interventions: Procedure: EUS-FNA, Device: nCLE | Intervention Type: PROCEDURE; Name: EUS-FNA; Assigned to Arm(s): Lymph nodes, pancreatic masses & cysts | Intervention Type: DEVICE; Name: nCLE; Assigned to Arm(s): Lymph nodes, pancreatic masses & cysts
C: Arm Label: EUS-FNB with 25-gauge; Type: EXPERIMENTAL; Interventions: Device: EUS-FNB with 25-gauge (Echotip ProCore; Cook Endoscopy Inc, Limerick, Ireland) | Intervention Type: DEVICE; Name: EUS-FNB with 25-gauge (Echotip ProCore; Cook Endoscopy Inc, Limerick, Ireland); Assigned to Arm(s): EUS-FNB with 25-gauge
D: Intervention Type: DEVICE; Name: Direct visualization and needle based confocal laser-induced endomicroscopy miniprobe; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Blood transfusion during perioperative period in patients undergoing to major surgery has been associated to several postoperative complications. Particularly in oncologic surgery, red blood cell transfusion has been investigated as a factor of worse outcome and cancer recurrence due to postoperative impairment of cellular immunity. Although red blood cell transfusion has decreased in worldwide clinical practice, this issue still remains a matter of controversy in oncologic surgery. There are no prospective studies comparing outcomes between restrictive or liberal of blood transfusion strategy in oncologic surgery. This study is a prospective and randomized study comparing clinical outcomes between two strategies of transfusion in oncologic surgery - liberal or restrictive


Options:
A: Arm Label: Liberal Group; Type: EXPERIMENTAL; Interventions: Other: Haemoglobin 9.5 g/dL | Arm Label: Restrictive group; Type: ACTIVE_COMPARATOR; Interventions: Other: Haemoglobine 7.5g/dL | Intervention Type: OTHER; Name: Haemoglobin 9.5 g/dL; Assigned to Arm(s): Liberal Group | Intervention Type: OTHER; Name: Haemoglobine 7.5g/dL; Assigned to Arm(s): Restrictive group
B: Arm Label: Restrictive transfusion strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Restrictive Transfusion Strategy | Arm Label: Liberal transfusion strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Liberal transfusion strategy | Intervention Type: OTHER; Name: Restrictive Transfusion Strategy; Assigned to Arm(s): Restrictive transfusion strategy | Intervention Type: OTHER; Name: Liberal transfusion strategy; Assigned to Arm(s): Liberal transfusion strategy
C: Arm Label: Liberal RBC Transfusion Strategy; Type: EXPERIMENTAL; Interventions: Other: Liberal Red Blood Cell Transfusion Strategy | Arm Label: Restrictive RBC Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Restrictive Red Blood Cell Transfusion Strategy | Intervention Type: OTHER; Name: Liberal Red Blood Cell Transfusion Strategy; Assigned to Arm(s): Liberal RBC Transfusion Strategy | Intervention Type: OTHER; Name: Restrictive Red Blood Cell Transfusion Strategy; Assigned to Arm(s): Restrictive RBC Transfusion Strategy
D: Arm Label: Liberal Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell transfusion | Arm Label: Restrictive Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell transfusion | Intervention Type: OTHER; Name: Red blood cell transfusion; Assigned to Arm(s): Liberal Transfusion Strategy | Intervention Type: OTHER; Name: Red blood cell transfusion; Assigned to Arm(s): Restrictive Transfusion Strategy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Blood transfusion during perioperative period in patients undergoing to major surgery has been associated to several postoperative complications. Particularly in oncologic surgery, red blood cell transfusion has been investigated as a factor of worse outcome and cancer recurrence due to postoperative impairment of cellular immunity. Although red blood cell transfusion has decreased in worldwide clinical practice, this issue still remains a matter of controversy in oncologic surgery. There are no prospective studies comparing outcomes between restrictive or liberal of blood transfusion strategy in oncologic surgery. This study is a prospective and randomized study comparing clinical outcomes between two strategies of transfusion in oncologic surgery - liberal or restrictive


Options:
A: Arm Label: Liberal Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell transfusion | Arm Label: Restrictive Transfusion Strategy; Type: ACTIVE_COMPARATOR; Interventions: Other: Red blood cell transfusion | Intervention Type: OTHER; Name: Red blood cell transfusion; Assigned to Arm(s): Liberal Transfusion Strategy | Intervention Type: OTHER; Name: Red blood cell transfusion; Assigned to Arm(s): Restrictive Transfusion Strategy
B: Arm Label: Liberal blood transfusion; Type: ACTIVE_COMPARATOR; Interventions: Biological: SAGM (Saline-Adenine-Glucose-Mannitol) blood transfusion | Arm Label: Restrictive blood transfusion; Type: ACTIVE_COMPARATOR; Interventions: Biological: SAGM (Saline-Adenine-Glucose-Mannitol) blood transfusion | Intervention Type: BIOLOGICAL; Name: SAGM (Saline-Adenine-Glucose-Mannitol) blood transfusion; Assigned to Arm(s): Liberal blood transfusion | Intervention Type: BIOLOGICAL; Name: SAGM (Saline-Adenine-Glucose-Mannitol) blood transfusion; Assigned to Arm(s): Restrictive blood transfusion
C: Arm Label: Restrictive RBC Transfusion Group; Type: EXPERIMENTAL; Interventions: Biological: Restrictive RBC Transfusion | Arm Label: Liberal RBC Transfusion Group; Type: EXPERIMENTAL; Interventions: Biological: Liberal RBC Transfusion | Intervention Type: BIOLOGICAL; Name: Restrictive RBC Transfusion; Assigned to Arm(s): Restrictive RBC Transfusion Group | Intervention Type: BIOLOGICAL; Name: Liberal RBC Transfusion; Assigned to Arm(s): Liberal RBC Transfusion Group
D: Arm Label: Liberal; Type: EXPERIMENTAL; Interventions: Drug: red blood cell transfusion trigger | Arm Label: Restrictive; Type: ACTIVE_COMPARATOR; Interventions: Drug: red blood cell transfusion trigger | Intervention Type: DRUG; Name: red blood cell transfusion trigger; Assigned to Arm(s): Liberal, Restrictive

Answer: A